Korean J Psychopharmacol.
2007 Mar;18(2):92-102.
Body Weight Gain and Metabolic Changes in Patients with Schizophrenia during 12-Week Randomized Treatment of Ziprasidone and Risperidone
- Affiliations
-
- 1Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea. kys@snu.ac.kr
- 2Institute of Human Behavioral Medicine, Seoul National University College of Medicine, Seoul, Korea.
- 3Department of Psychiatry, The Catholic University of Korea, Medical College, Seoul, Korea.
- 4Department of Psychiatry, Samsung Seoul Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
- 5Department of Neuropsychiatry, Inje University School of Medicine, Busan, Korea.
- 6Department of Psychiatry, Asan Medical Center, Ulsan University College of Medicine, Seoul, Korea.
- 7Department of Psychiatry, Inha University College of Medicine, Incheon, Korea.
- 8Department of Psychiatry, Yonsei University Wonju College of Medicine, Wonju, Korea.
- 9Department of Neuropsychiatry, Wonkwang University School of Medicine, Iksan, Korea.
- 10Department of Psychiatry, Seoul Bukbu Geriatric Hospital, Seoul, Korea.
- 11Department of Psychiatry, Yonsei University College of Medicine, Seoul, Korea.
Abstract
OBJECTIVE
Body weight gain and metabolic syndrome are frequent adverse side effects of atypical antipsychotics. However, ziprasidone has been reported to have less effect on body weight and other metabolic parameters of patients, such as blood glucose and cholesterol. In this study, changes in the body weight and metabolic parameters were compared between the treatment groups of ziprasidone and risperidone in the patients with schizophrenia or schizoaffective disorder.
METHODS
Patients shown acute exacerbation of schizophrenia or schizoaffective disorder diagnosed by DSM-IV diagnostic criteria were randomly assigned to ziprasidone 40-80 mg b.i.d. (N=56) or risperidone 1-4 mg b.i.d. (N=56) for 12 weeks. Body weight was measured before treatment and at 1st, 2nd, 4th, 6th, 12th week after treatment. The serum levels of glucose and cholesterol were checked before treatment and 12th week after treatment, and serum levels of prolactin before treatment and at 4th and 12th week after treatment.
RESULTS
Less gain of body weight was shown in the patients treated with ziprasidone compared to those treated with risperidone. Mean body weight gain for 12 weeks were 0.8 kg and 3.5 kg in the ziprasidone and risperidone group, respectively. There was significant difference in weight gain between these two groups from 4th week. Serum prolactin elevation was higher in the risperidone group than in the ziprasidone group. However, there were no significant differences in the effects on the level of blood glucose and cholesterol between two treatment groups.
CONCLUSION
This study shows that ziprasidone had less effect on body weight and prolactin compared to risperidone in the patients with schizophrenia or schizoaffective disorder in Korea. Although further studies are necessary to investigate the long-term effects, the less effect of ziprasidone on body weight and serum prolactin in schizophrenia and schizoaffective patients in Korea may help to enhance treatment compliance and lessen the cardiovascular risks.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Effect of Topiramate on Risperidone-Induced Weight Gain: A Pilot Study
- The Influences of Risperidone and Clozapine on Body Weight and Glucose Level in Patients with Chronic Schizophrenia: Comparison Study with Haloperidol
- Metabolic Disturbances Independent of Body Mass in Patients with Schizophrenia Taking Atypical Antipsychotics
- Correlation between Plasma Ghrelin Levels and Risperidone Induced Weight Gain
- The Tolerability of Mirtazapine Augmentation in Schizophrenic Patients Treated with Risperidone: A Preliminary Randomized Placebo-controlled Trial
